Texas Children’s Hospital 
Welcome,         Profile    Billing    Logout  
 3 Products   2 Diseases   3 Products   2 Trials   32 News 


12»
  • ||||||||||  IndoVac (SARS-CoV-2 protein subunit recombinant vaccine) / Bio Farma Indonesia
    Trial completion:  Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine (clinicaltrials.gov) -  Nov 29, 2023   
    P3,  N=4050, Completed, 
    Trial primary completion date: Apr 2024 --> Apr 2025 Active, not recruiting --> Completed
  • ||||||||||  IndoVac (SARS-CoV-2 protein subunit recombinant vaccine) / Bio Farma Indonesia
    Trial completion date, Trial primary completion date:  Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children (clinicaltrials.gov) -  Apr 19, 2023   
    P3,  N=1050, Recruiting, 
    Results obtained from this study will ultimately help to enhance the antitumor efficacy of NKT cell-based cancer immunotherapy. Trial completion date: Dec 2022 --> Jan 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  IndoVac (SARS-CoV-2 protein subunit recombinant vaccine) / Bio Farma Indonesia
    Trial completion:  Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine (clinicaltrials.gov) -  Apr 13, 2023   
    P2/3,  N=360, Completed, 
    Trial completion date: Dec 2022 --> Jan 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Active, not recruiting --> Completed
  • ||||||||||  IndoVac (SARS-CoV-2 protein subunit recombinant vaccine) / Bio Farma Indonesia
    Enrollment closed:  Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine (clinicaltrials.gov) -  Sep 16, 2022   
    P3,  N=4050, Active, not recruiting, 
    Phase classification: P2/3 --> P3 Recruiting --> Active, not recruiting
  • ||||||||||  IndoVac (SARS-CoV-2 protein subunit recombinant vaccine) / Bio Farma Indonesia
    Trial completion, Trial completion date:  Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine (clinicaltrials.gov) -  Aug 9, 2022   
    P1,  N=54, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: May 2022 --> Aug 2022
  • ||||||||||  IndoVac (SARS-CoV-2 protein subunit recombinant vaccine) / Bio Farma Indonesia
    Enrollment closed, Enrollment change:  Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine (clinicaltrials.gov) -  Jul 1, 2022   
    P2/3,  N=360, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: May 2022 --> Aug 2022 Recruiting --> Active, not recruiting | N=3960 --> 360
  • ||||||||||  IndoVac (SARS-CoV-2 protein subunit recombinant vaccine) / Bio Farma Indonesia
    Enrollment closed:  Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine (clinicaltrials.gov) -  Apr 21, 2022   
    P1,  N=54, Active, not recruiting, 
    Trial completion date: May 2022 --> Nov 2022 Recruiting --> Active, not recruiting
  • ||||||||||  IndoVac (SARS-CoV-2 protein subunit recombinant vaccine) / Bio Farma Indonesia
    Enrollment open:  Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine (clinicaltrials.gov) -  Apr 18, 2022   
    P2/3,  N=3960, Recruiting, 
    LEF1 maintains central memory-like differentiation in CD62L+ NKTs, and transgenic overexpression of LEF1 helps CAR-NKTs resist exhaustion and boosts therapeutic efficacy in a NB model. Not yet recruiting --> Recruiting
  • ||||||||||  IndoVac (SARS-CoV-2 protein subunit recombinant vaccine) / Bio Farma Indonesia
    Phase classification, Enrollment change:  Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine (clinicaltrials.gov) -  Dec 23, 2021   
    P1,  N=60, Not yet recruiting, 
    Not yet recruiting --> Recruiting Phase classification: P1/2 --> P1 | N=780 --> 60
  • ||||||||||  KUR-502 / Athenex
    Trial completion date, Trial initiation date, Trial primary completion date:  CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov) -  Nov 15, 2019   
    P1,  N=20, Not yet recruiting, 
    Trial primary completion date: Sep 2019 --> Sep 2021 Trial completion date: Mar 2034 --> Mar 2035 | Initiation date: Mar 2019 --> Mar 2020 | Trial primary completion date: Apr 2022 --> Apr 2023
  • ||||||||||  Cytorex EBV (baltaleucel-T) / Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital, Athenex
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma (clinicaltrials.gov) -  Jan 14, 2019   
    P2,  N=15, Terminated, 
    Trial completion date: Mar 2034 --> Mar 2035 | Initiation date: Mar 2019 --> Mar 2020 | Trial primary completion date: Apr 2022 --> Apr 2023 Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Apr 2018 | N=35 --> 15 | Trial completion date: Sep 2019 --> Sep 2018; Insufficient enrollment rate
  • ||||||||||  Cytorex EBV (baltaleucel-T) / Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital, Athenex
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  CIVIC: Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (clinicaltrials.gov) -  Jan 14, 2019   
    P2,  N=1, Terminated, 
    Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Apr 2018 | N=35 --> 15 | Trial completion date: Sep 2019 --> Sep 2018; Insufficient enrollment rate N=70 --> 1 | Trial completion date: Oct 2019 --> Feb 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Feb 2018; Insufficient recruitment rate
  • ||||||||||  KUR-501 / Athenex
    Trial completion date, Trial initiation date, Trial primary completion date:  GINAKIT2: GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children with Neuroblastoma (clinicaltrials.gov) -  Sep 11, 2018   
    P1,  N=24, Recruiting, 
    N=70 --> 1 | Trial completion date: Oct 2019 --> Feb 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Feb 2018; Insufficient recruitment rate Trial completion date: May 2035 --> Aug 2034 | Initiation date: May 2019 --> Jan 2018 | Trial primary completion date: Jun 2020 --> Sep 2019
  • ||||||||||  Cytorex EBV (baltaleucel-T) / Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital, Athenex
    Trial primary completion date:  Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma (clinicaltrials.gov) -  Apr 10, 2017   
    P2,  N=35, Recruiting, 
    N=18 --> 0 | Initiation date: Aug 2016 --> Aug 2017 | Not yet recruiting --> Withdrawn Trial primary completion date: Dec 2017 --> Sep 2018
  • ||||||||||  Cytorex EBV (baltaleucel-T) / Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital, Athenex
    Trial primary completion date:  Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma (clinicaltrials.gov) -  Dec 28, 2016   
    P2,  N=30, Recruiting, 
    Trial primary completion date: Dec 2017 --> Sep 2018 Trial primary completion date: Jun 2017 --> Dec 2017